CAJ | 학술논문

目的:评价雷帕霉素滴眼液与环孢霉素A滴眼液联合应用对大鼠角膜移植免疫排斥反应的抑制作用.方法:建立大鼠穿透性角膜移植动物模型,以SD大鼠为受体,Wistar大鼠为供体,分为A,B,C,D4组.手术后2d术眼分别滴用滴眼液基质100μL,2g/L雷帕霉素滴眼液100μL,10g/L环孢霉素A滴眼液100μL,2g/L雷帕霉素滴眼液50μL+10g/L环孢霉素A滴眼液50μL,4次/d,连续用药至排斥反应发生.对角膜植片进行临床观察,记录植片存活时间,并进行组织学检查.结果:各治疗组显著延长角膜植片存活时间(P＜0.01),联合用药的D组效果更佳,优于各单药物治疗组B组和C组(P＜0.05,P＜0.01).组织学发现,术后14d各治疗组炎细胞浸润、新生血管形成及水肿程度明显轻于对照组.结论:局部联合应用雷帕霉素滴眼液与环孢霉素A滴眼液能显著延长角膜植片存活时间,抑制大鼠角膜移植排斥反应,具有协同作用.
목적:평개뢰파매소적안액여배포매소A적안액연합응용대대서각막이식면역배척반응적억제작용.방법:건립대서천투성각막이식동물모형,이SD대서위수체,Wistar대서위공체,분위A,B,C,D4조.수술후2d술안분별적용적안액기질100μL,2g/L뢰파매소적안액100μL,10g/L배포매소A적안액100μL,2g/L뢰파매소적안액50μL+10g/L배포매소A적안액50μL,4차/d,련속용약지배척반응발생.대각막식편진행림상관찰,기록식편존활시간,병진행조직학검사.결과:각치료조현저연장각막식편존활시간(P＜0.01),연합용약적D조효과경가,우우각단약물치료조B조화C조(P＜0.05,P＜0.01).조직학발현,술후14d각치료조염세포침윤、신생혈관형성급수종정도명현경우대조조.결론:국부연합응용뢰파매소적안액여배포매소A적안액능현저연장각막식편존활시간,억제대서각막이식배척반응,구유협동작용.
· AIM: To evaluate the combined effect of rapamycin ophthalmic solution and cyclosporin A ophthalmic solution on allogeneic transplantation in a rat model.rats were used as donors. The animals were randomly assigned to 4 groups. Group A: control (ophthalmic solution solvent 100μ L); group B: 2g/L rapamycin ophthalmic solution 100μ L; group C: 10g/L cyclosporin A ophthalmic solution 100μ L; group D: 2g/L rapamycin ophthalmic solution 50μ L and 10g/L cyclosporin A ophthalmic solution 50μ L, 4 times every day. The treatment was started on 2d after operation, and the animals were administered until rejection. The grafts were inspected by slit-lamp microscope and the corneal survival time was recorded. The pathologic changes were measured by light microscope.significantly prolonged compared with the control group (P ＜ 0.01). However, the combined therapy (group D) was significantly superior compared with group B and C (P＜0.05, P＜ 0.01). The histopathological findings showed that the inflammation cells, neovascularity in each treated group were significantly fewer than that in control group at 14d after operation.a double drug regimen with rapamycin ophthalmic solution and cyclosporin A ophthalmic solution for the control of acute corneal allograft rejection. It indicats that the combined therapy produced synergistic effect.